Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 435Recruiting 170Terminated 130Active not recruiting 129Unknown 41Not yet recruiting 31Withdrawn 27Suspended 2Enrolling by invitation 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

zilucoplan 1toripalimab 1somapacitan 1rozanolixizumab 1pembrolizumab 1ibrutinib 1futibatinib 1exemestane 1enzalutamide 1durvalumab 1decitabine and cedazuridine drug combination 1cemiplimab 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Tamoxifen 1Robotic Surgical Procedures 1Observation 1Letrozole 1Lenalidomide 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Fulvestrant 1Folfox protocol 1Dexamethasone 1Cisplatin 1Carboplatin 1Bevacizumab 1Anastrozole 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × INDUSTRY × Carboplatin × Clear all
NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Shandong New Time Pharmaceutical Co., LTD

Phase 2/3 Enrolling by invitation
510 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡